Genmab A achieved in the fourth quarter 2025, above Company average Revenue surge of 169.18% year on year, to $ 3,720.00 millions.
Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 26 other companies have achieved higher Revenue growth. While Genmab A' s Revenue doubling of 169.18% ranks overall at the positon no. 137 in the fourth quarter 2025.
With the quarterly Revenue reported in the Dec 31 2025 period, Genmab A's cumulative twelve months Revenue were $ 3,720 millions, company would post below average annual Revenue growth of -13.49% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Genmab A's Revenue growth from the 0% growth in Dec 31 2024.
In the Healthcare sector 484 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3826.
With the quarterly Revenue reported in the Dec 31 2025 period, Genmab A's cumulative twelve months Revenue were $ 3,720 millions, company would post below average annual Revenue growth of -13.49% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Genmab A's Revenue growth from the 0% growth in Dec 31 2024.
In the Healthcare sector 484 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3826.
About Genmab A Revenue Growth Rates (GMAB), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
287.83%